Skip to content. | Skip to navigation

Personal tools
Log in
You are here: Home Know-who Know-how Directory From A to Z Kiadis Pharma

Kiadis Pharma

Business focus: Kiadis Pharma focuses on the development and commercialisation of advanced treatments for end-stage blood cancer patients. The company aims to shift the frontier in areas with high unmet medical need.

Kiadis Pharma

Kiadis Pharma
Entrada 231-234
1096 EG  Amsterdam
Website Kiadis Pharma
E-mail Kiadis Pharma
T +31 (0)20 314 02 50
F +31 (0)20 314 02 51

Employees in Amsterdam: 25
Employees in R&D: 0
Year of foundation: 1997

Company Profile

Kiadis Pharma is an oncology focused biopharmaceutical development company with cell based products in clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures. Kiadis Pharma is located in Amsterdam, The Netherlands. For more information about Kiadis Pharma, please visit www.kiadis.com.

Science and Technologies or Services

  • Four products in various stages of clinical development
  • Three product development engines

Alliances

Kiadis Pharma aims to bring its blood cancer products to market independently. Therefore a very conservative partnering strategy is followed. Main alliances are with internationally renowned key opinion leaders in the field of Bone Marrow Transplantation.

Keywords

  • Haematology;
  • Oncology;
  • Clinical;
  • Bone marrow transplantation;
  • Photodynamic therapy.


Document Actions

Find your life sciences partner in the Amsterdam BioMed Cluster

Find your life sciences partner in the Amsterdam BioMed Cluster

Column

Penny-wise!

Synaps bij column Arjen Brussaard, foto CNCR.nl

By Arjen Brussaard

Recently the topsector plan Life Sciences & Health was published and presented to Minister Verhagen, of the so-called ELI Ministry. The document is an amazing compressed 60-pager, based on months of hard work by the group of experts chaired by Roel Fonville, and summarizes the conclusions after dozens of 1-to-1 meetings, five regional group sessions with dozens of opinion leaders and after having received over 170 (!) memo's, white papers and letters of intent.
More...